摘要
目的探讨细胞因子激活杀伤（CIK）细胞治疗晚期非小细胞肺癌的临床疗效。方法采集患者外周血单个核细胞用无血清培养基经白介素2（IL-2）、干扰素（IFN-γ）、CD3McAb、白介素1α（IL-1α）诱导，制备CIK细胞，培养14d后分次回输给患者，观察患者治疗前后临床症状改善、瘤体变化、肿瘤标志物变化和免疫指标的变化。结果在46例接受CIK细胞治疗中，临床症状治疗前后有明显改善；CD3＋和CD4＋／CD8＋比值差异均有统计学意义（P〈0．05）；肿瘤标志物SCC差异有统计学意义（P〈0．05）。结论CIK细胞对手术和放疗已无适应证的晚期非小细胞肺癌患者提供了一种可以延长生存期、提高生活质量的新途径。CIK细胞过继免疫治疗是一种非常有前景的抗肿瘤治疗方法。
Objective To investigate the clinical effects on patients with advhnced non - small cell lung cancer with cytokine - induced killer cells（CIK）. Methods CIK cells were induced by culturing PBMC of patients by incubation in vitro with IL - 2 .IFN -γ.anti - CD3 monoclonal antibody and IL- 1 α in two weeks, then were transfused back to the patients, for observation clinical symptoms, tumor volume, life quality, tumor markers and immunity indexes. Results The SCC from patients was significantly lower than that before transfused （ P 〈 0.05 ）, The CD4, CD4 ＋/CD8 ＋ were significantly higher than that before transfused （ P 〈 0.05 ） Conclusions The results suggests that CIK cells therapy can improve the effect of the cancer therapy and improve survival quantity. Its can provide a potent immune therapeutic strategy for patients with advanced non - small cell lung cancer.
出处
《中外医学研究》
2009年第8期30-31,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
